Biomedical subjects

N Carpentier

Publications and source records attributed to N Carpentier.

23 records · Page 2Linked to original sources

PubMed1980

Serial measurement of circulating immune complexes in the sera of patients with leukaemia.

The occurrence of circulating immune complexes was studied in 220 sera of 86 patients with leukaemia. Three tests were used in parallel: the 125I-C1q-binding assay, the complement consumption test and C1q solubility test. Positive results in at least two assays were found in 64% of the patients and in 88% of the 32 serially investigated patients. An association was found between the elevated immune complex level and the blastic phase of the disease. A fluctuation of the immune complex level-independent of the clinical course of leukaemia-could also be demonstrated. The peaks of these types of fluctuations obtained by the different tests did not coincide on several occasions. These findings suggest that the composition of immune complexes changes in the course of the disease.

Antigen-Antibody Complex↗

PubMed1978

[Immunologic study of pleural neoplastic effusions: Detection of immune complexes and complement activation].

Occurrence of immune complexes in malignant pleural effusions has been investigated by the 125I-c1q binding test. 55% of the pleural effusions had C1q binding activity levels higher than those found in transudates used as controls. The levels of C1q binding activity in effusions were significantly higher than those found in the serum of the same cancer patients. High levels of C1q binding activity were found in malignant effusion independently of type or differentiation of the tumors involved. The C1q binding material had properties of immune complexes. The levels of CH50 and C3d, i.e. the degradation product of C3, in malignant effusion were similar to those of transudates. These observations show a high incidence of immune complexes in malignant effusions and a slight activation of complement inadequate for its local consumption. The persistence in major quantity of immune complexes in malignant effusion suggests local formation or decreased clearance.

Antigen-Antibody Complex↗

PubMed1977

Circulating immune complexes in patients with malignant lymphomas and solid tumors.

Sera from 50 patients with Hodgkin's disease, 78 patients with non-Hodgkin non-leukemic malignant lymphomas, and 75 patients with different types of solid malignant tumors were investigated for the presence of immune complexes using the (125I) C1q-binding test. All patients were untreated. An increased serum C1q-binding activity was found in 22% of the patients with Hodgkin's disease, 35.9% of the non-Hodgkin lymphoma patients and in 37.3% of the patients with solid tumors. The C1q-binding material detected in the patients' sera had properties similar to those of immune complexes. On sucrose density gradient it sedimented as a 10-30 s material. It contained IgG which were dissociated under acid conditions. Passage through anti-IgG immunoabsorbent removed its C1q-binding properties. A prevalent association was found between the presence of serum immune complexes and disseminated disease stages in all the patient groups included. A similar association was found between the presence of serum immune complexes and general symptoms among the malignant lymphoma patients. The nature of the antigens involved in the complexes remains unknown.

Adult↗

PubMed1976

The occurrence of antibodies against single-stranded DNA in the sera of patients with acute and chronic leukaemia.

One hundred and seventy-five sera from thirty-three patients with acute myeloid leukaemia, forty-two patients with chronic myeloid leukaemia and twelve patients with acute lymphatic leukaemia were examined by a radioimmunological technique for the presence of antibodies against single-stranded and double-stranded DNA. The levels of single-stranded DNA binding activity was significantly higher in all three types of leukaemia compared to those of healthy controls. In contrast, none of these sera exhibited a positive reaction with double-stranded DNA. In some cases the level of serum anti-DNA antibodies increased after the decrease of the leucocyte count. The presence of anti-DNA antibodies in leukaemic patients may have some biological significance.

Antibodies, Neoplasm↗

PubMedDate not supplied

[Methotrexate and non-steroidal anti-inflammatory agent combination in rheumatoid arthritis].

It is well known that methotrexate (MTX), used at high dosage in cancer patients, must not be combined with a non-steroidal anti-inflammatory drug (NSAID) because of high risk of side effects; prescribed at low dosage (< or = 15 mg per week) in rheumatoid arthritis patients, MTX is often combined with an NSAID. Some cases reported in the literature underline the potential toxicity of the association of low dose MTX with an NSAID, but most of the pharmacological studies do not confirm this hypothesis. Except for salicylates, NSAIDs do not affect the absorption, distribution, protein binding, area under the curve, half-life, or the elimination of MTX. Therefore, if necessary, MTX (< or = 15 mg per week) can be combined with an NSAID during the treatment of rheumatoid arthritis.

Anti-Inflammatory Agents, Non-Steroidal↗